bioAffinity Technologies Announces Collaboration with Pictor on Lung Diagnostics

What Happened
bioAffinity Technologies, Inc. (BIAF) filed an 8‑K on July 22, 2026, announcing a collaboration with Pictor, Inc., a targeted proteomic platform company. The partnership is intended to support development and commercialization of bioAffinity’s next‑generation diagnostic tests aimed at providing a more complete picture of lung inflammation in patients with asthma and COPD. A press release dated July 22, 2026 was attached to the filing as Exhibit 99.1.

Key Details

• Filing date: July 22, 2026 (Form 8‑K).
• Partner: Pictor, Inc. — described as a targeted proteomic platform company.
• Purpose: Joint support for development and commercialization of next‑generation diagnostic tests to assess lung inflammation in asthma and COPD.
• Press release: Issued July 22, 2026 and included as Exhibit 99.1 to the 8‑K.

Why It Matters
This announcement signals an operational partnership intended to advance bioAffinity’s diagnostic pipeline for respiratory diseases, specifically asthma and COPD. For investors, the collaboration could affect the company’s product development timeline and commercialization prospects; however, the 8‑K does not disclose financial terms, revenue impacts, or specific milestones. Review the attached press release for further detail and watch for subsequent filings or updates that provide commercial terms, development milestones, or financial guidance.